Literature DB >> 12717346

The role of PTEN in the progression and survival of prostate cancer.

N D Deocampo1, H Huang, D J Tindall.   

Abstract

PTEN (phosphatase and tensin homologue deleted on chromosome-10), a dual specificity phosphatase, is a tumor suppressor gene whose inactivation has been associated with many different types of cancer including prostate cancer. Prostate adenocarcinoma is one of the most commonly diagnosed malignancies afflicting the male population in both the United States and Europe. The frequency of PTEN inactivation appears to increase during the progression of prostatic cancer. The physical loss of the PTEN genetic locus in prostate cancer progression has been well characterized, however the molecular implication of this loss of PTEN remains enigmatic. The purpose of this review is to describe the functional role of PTEN in the molecular pathogenesis of prostatic disease. We review the function of PTEN discussing its association with the phosphoinositol 3-kinase (PI3K) and mitogen activated protein kinase (MAPK) signal transduction pathways. Additionally, we discuss the role of PTEN in the regulation of apoptotic pathways involving the anti-apoptotic gene bcl-2 and the pro-apoptotic ligand TRAIL. We also review the mechanisms that can lead to the loss of PTEN function. We describe genetic inactivation including loss of heterozygosity, haploinsufficiency and mutation. We conclude by outlining epigenetic loss including methylation, post-translational modifications and oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12717346

Source DB:  PubMed          Journal:  Minerva Endocrinol        ISSN: 0391-1977            Impact factor:   2.184


  30 in total

1.  Aloe-emodin suppresses prostate cancer by targeting the mTOR complex 2.

Authors:  Kangdong Liu; Chanmi Park; Shengqing Li; Ki Won Lee; Haidan Liu; Long He; Nak Kyun Soung; Jong Seog Ahn; Ann M Bode; Ziming Dong; Bo Yeon Kim; Zigang Dong
Journal:  Carcinogenesis       Date:  2012-04-24       Impact factor: 4.944

2.  A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer.

Authors:  Andrew J Armstrong; George J Netto; Michelle A Rudek; Susan Halabi; David P Wood; Patricia A Creel; Kelly Mundy; S Lindsay Davis; Ting Wang; Roula Albadine; Luciana Schultz; Alan W Partin; Antonio Jimeno; Helen Fedor; Phillip G Febbo; Daniel J George; Robin Gurganus; Angelo M De Marzo; Michael A Carducci
Journal:  Clin Cancer Res       Date:  2010-05-25       Impact factor: 12.531

3.  SLUG is a direct transcriptional repressor of PTEN tumor suppressor.

Authors:  Berna Uygur; Katrina Abramo; Evgenia Leikina; Calvin Vary; Lucy Liaw; Wen-Shu Wu
Journal:  Prostate       Date:  2015-03-01       Impact factor: 4.104

Review 4.  Stem cells in prostate cancer initiation and progression.

Authors:  Devon A Lawson; Owen N Witte
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

Review 5.  Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer.

Authors:  Christopher J Logothetis; Gary E Gallick; Sankar N Maity; Jeri Kim; Ana Aparicio; Eleni Efstathiou; Sue-Hwa Lin
Journal:  Cancer Discov       Date:  2013-06-28       Impact factor: 39.397

6.  Threonine-120 phosphorylation regulated by phosphoinositide-3-kinase/Akt and mammalian target of rapamycin pathway signaling limits the antitumor activity of mammalian sterile 20-like kinase 1.

Authors:  Filiz Kisaayak Collak; Kader Yagiz; Daniel J Luthringer; Bahriye Erkaya; Bekir Cinar
Journal:  J Biol Chem       Date:  2012-05-22       Impact factor: 5.157

7.  KDM5B Is Essential for the Hyperactivation of PI3K/AKT Signaling in Prostate Tumorigenesis.

Authors:  Guoliang Li; Thanigaivelan Kanagasabai; Wenfu Lu; Mike R Zou; Shang-Min Zhang; Sherly I Celada; Michael G Izban; Qi Liu; Tao Lu; Billy R Ballard; Xinchun Zhou; Samuel E Adunyah; Robert J Matusik; Qin Yan; Zhenbang Chen
Journal:  Cancer Res       Date:  2020-08-31       Impact factor: 12.701

8.  Aberrant cytoplasm localization and protein stability of SIRT1 is regulated by PI3K/IGF-1R signaling in human cancer cells.

Authors:  Vanessa Byles; Laura K Chmilewski; Joyce Wang; Lijia Zhu; Lora W Forman; Douglas V Faller; Yan Dai
Journal:  Int J Biol Sci       Date:  2010-10-07       Impact factor: 6.580

Review 9.  Cellular prostatic acid phosphatase, a PTEN-functional homologue in prostate epithelia, functions as a prostate-specific tumor suppressor.

Authors:  Sakthivel Muniyan; Matthew A Ingersoll; Surinder K Batra; Ming-Fong Lin
Journal:  Biochim Biophys Acta       Date:  2014-04-18

10.  RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid.

Authors:  Todd M Morgan; Tiffany E M Pitts; Ted S Gross; Sandra L Poliachik; Robert L Vessella; Eva Corey
Journal:  Prostate       Date:  2008-06-01       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.